Genmab (GNMSF)
(Delayed Data from OTC)
$274.35 USD
+4.48 (1.66%)
Updated Apr 26, 2024 03:26 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Genmab AS falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,392 | 2,067 | 1,349 | 1,549 | 804 |
Cost Of Goods | 33 | 0 | 0 | 0 | 0 |
Gross Profit | 2,359 | 2,067 | 1,349 | 1,549 | 804 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,587 | 1,167 | 869 | 582 | 409 |
Income After Depreciation & Amortization | 773 | 900 | 480 | 967 | 395 |
Non-Operating Income | 183 | 192 | 265 | 176 | 34 |
Interest Expense | 137 | 96 | 112 | 239 | 1 |
Pretax Income | 818 | 996 | 634 | 904 | 429 |
Income Taxes | 187 | 214 | 155 | 176 | 104 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 632 | 782 | 479 | 729 | 325 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 632 | 782 | 479 | 729 | 325 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 815 | 951 | 520 | 1,007 | 416 |
Depreciation & Amortization (Cash Flow) | 43 | 51 | 39 | 40 | 21 |
Income After Depreciation & Amortization | 773 | 900 | 480 | 967 | 395 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.92 | 65.39 | 65.72 | 65.18 | 63.64 |
Diluted EPS Before Non-Recurring Items | 11.80 | 11.85 | 7.24 | 11.18 | 5.10 |
Diluted Net EPS (GAAP) | 9.59 | 11.84 | 7.25 | 11.06 | 5.10 |
Fiscal Year end for Genmab AS falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 674.81 | 692.62 | 613.33 | 411.26 |
Cost Of Goods | NA | 18.22 | 14.60 | 0.00 | 0.00 |
Gross Profit | NA | 656.60 | 678.02 | 613.33 | 411.26 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 416.36 | 427.34 | 394.61 | 348.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 240.24 | 250.68 | 218.72 | 62.97 |
Non-Operating Income | NA | -43.56 | 149.80 | 35.50 | 40.92 |
Interest Expense | NA | 65.63 | 5.99 | 2.48 | 62.68 |
Pretax Income | NA | 131.06 | 394.49 | 251.73 | 41.21 |
Income Taxes | NA | 40.81 | 83.66 | 53.47 | 8.65 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 90.25 | 310.83 | 198.26 | 32.57 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 90.25 | 310.83 | 198.26 | 32.57 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 66.18 | 66.07 | 65.84 | 65.89 |
Diluted EPS Before Non-Recurring Items | NA | 3.63 | 4.72 | 3.01 | 0.49 |
Diluted Net EPS (GAAP) | NA | 1.36 | 4.72 | 3.01 | 0.49 |